B
Bunchoo Pongtanakul
Researcher at Mahidol University
Publications - 31
Citations - 444
Bunchoo Pongtanakul is an academic researcher from Mahidol University. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Thalassemia. The author has an hindex of 8, co-authored 27 publications receiving 361 citations. Previous affiliations of Bunchoo Pongtanakul include University of Toronto & Siriraj Hospital.
Papers
More filters
Journal ArticleDOI
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
John D. Grainger,Franco Locatelli,Thirachit Chotsampancharoen,Elena K. Donyush,Bunchoo Pongtanakul,Patcharee Komvilaisak,Darintr Sosothikul,Guillermo Drelichman,Nongnuch Sirachainan,Susanne Holzhauer,Vladimir Lebedev,Richard S. Lemons,Dagmar Pospisilova,Ugo Ramenghi,James B. Bussel,Kalpana Bakshi,Malini Iyengar,Geoffrey W. Chan,Karen Chagin,Dickens Theodore,Lisa M Marcello,Christine K Bailey +21 more
TL;DR: The primary outcome was the proportion of patients achieving platelet counts of at least 50 × 10(9) per L in the absence of rescue therapy for 6 or more weeks from weeks 5 to 12 of the double-blind period.
Journal ArticleDOI
Outcome of children with aplastic anemia treated with immunosuppressive therapy.
TL;DR: Evaluation of the outcome of children with AA treated with IST finds no significant difference in the number of patients with or without an HLA‐matched sibling who receive immunosuppressive therapy.
Journal ArticleDOI
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Vip Viprakasit,Issarang Nuchprayoon,Ampaiwan Chuansumrit,Kitti Torcharus,Bunchoo Pongtanakul,Jiraporn Laothamatas,Somdet Srichairatanakool,Julaporn Pooliam,Siriwat Supajitkasem,Prapat Suriyaphol,Voravarn S. Tanphaichitr,Soodsarkorn Tuchinda +11 more
TL;DR: Monotherapy of deferiprone with appropriate dose adjustment and monitoring for adverse events appeared to be an effective chelation therapy in some patients with good compliance and acceptable safety profiles.
Journal ArticleDOI
Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia.
Ampaiwan Chuansumrit,Monthon Suwannuraks,Nantana Sri-Udomporn,Bunchoo Pongtanakul,Surapon Worapongpaiboon +4 more
TL;DR: Recombinant activated factor VII (rFVIIa), combined with local measures of fibrin glue and a celluloid splint, preventing bleeding from four invasive dental procedures is reported, showing to be an effective alternative to platelet concentrate in patients with Glanzmann thrombasthenia.
Journal ArticleDOI
Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.
Usanarat Anurathapan,Samart Pakakasama,Pimsiri Mekjaruskul,Nongnuch Sirachainan,Duantida Songdej,Ampaiwan Chuansumrit,Pimlak Charoenkwan,Arunee Jetsrisuparb,Kleebsabai Sanpakit,Bunchoo Pongtanakul,Piya Rujkijyanont,Arunotai Meekaewkunchorn,Rosarin Sruamsiri,Artit Ungkanont,Surapol Issaragrisil,Borje S. Andersson,Suradej Hongeng +16 more
TL;DR: It is suggested that class 3 HR thalassemia patients can safely receive HSCT with the novel RTC regimen and achieve the same excellent outcome as low/standard-risk thalassesmia patients who received the standard MAC regimen, and further, that this novel R TC approach should be tested in the low/ standard-risk patient population.